A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial presented June 5 in Chicago at the annual meeting of the American Society for Clinical Oncology (ASCO).
As part of the latest study findings, led by a researcher at ٺƵ Medical Center, injections of the experimental agent atezolizumab were found to shrink tumors by at least 30 percent and stall new tumor growth in 28 of 119 (or 24 percent of) patients, all of whom received the medication as their first therapy for metastic bladder cancer. Part of a new class of drugs known as checkpoint inhibitors, atezolizumab, also known by its brand name, Tecentriq, was last month approved by the Food and Drug Administration as a second-line treatment based on recent research from a related clinical trial presented in 2015.
“Our new study results argue that this treatment may be used as the first treatment for advanced bladder cancer for some patients,” says lead study investigator and medical oncologist Arjun V. Balar, MD, an assistant professor at ٺƵ and a member of its Laura and Isaac Perlmutter Cancer Center.
“Atezolizumab is the first therapy to be approved in more three decades for this disease, and is a new standard of care in the second-line setting,” says Balar. “Our results argue it may be best used as the first treatment for some patients.”
The current “first-line” standard of care in bladder cancer, Balar says, is cisplatin, a drug that kills tumor cells by preventing them from repairing damage to their DNA. In widespread use since the 1970s, cisplatin extends survival to slightly more than a year, but nearly half of bladder cancer patients, most of whom are elderly with other serious health issues, cannot take it because of its toxic side effects on nerve and kidney function, as well as hearing. Moreover, many patients’ cancers develop drug resistance to cisplatin and similar chemotherapy medications over time.
Balar says atezolizumab was well tolerated by all patients in the current study, which was conducted in medical centers across the United States, Canada, and Europe. Patients reported relatively mild instances of fatigue, itchy skin, and diarrhea, which represented far fewer and less-severe side effects than seen with cisplatin or its common alternative, carboplatin, Balar says.
In addition, half the patients who responded to the new therapy did so within 15 weeks, with almost all (21 out of 28) remaining on therapy without any detectable signs of cancer growth, at a dose of 1,200 milligrams every three weeks. As part of the study, all 21 patients with their cancer under control continue to be monitored, with some having continued to receive atezolizumab since the study started in May 2014.
Seven patients who initially responded to therapy eventually saw their cancer return and were referred for other therapies, along with those who did not initially respond to atezolizumab.
Patients who responded to therapy saw their tumors shrink or disappear altogether as part of a sustained immune response, with the shrinkages confirmed by radiological scans.
Balar says checkpoint inhibitors—some already approved to treat other forms of cancer—are designed to “retrain the immune system” to attack tumor cells by blocking the action of proteins believed to help cancer cells evade recognition by the immune system. While the drug’s precise mechanism of action is subject to further research by the team, the scientists say the new medication primarily blocks the interaction of the protein PD-L1, or programmed death ligand-1, with its programmed death receptor partner and checkpoint, PD-1. This “lock and key” connection, Balar says, is critical to the detection of tumor cells by immune system T cells.
An estimated 76,000 Americans will be diagnosed with bladder cancer in 2016. Less than 15 percent survive past five years if the disease is diagnosed in its advanced stages. Men are about three to four times more likely to get bladder cancer during their lifetime than women.
Balar is a paid consultant to Genentech, the manufacturer of atezolizumab and the company that funded the current study and all related clinical trials. Genentech is a subsidiary of Roche. Balar has also received research support from Merck, which is developing a competing immunotherapy to atezolizumab. The terms of these arrangements are being managed in accordance with the policies of ٺƵ.
In addition to Balar, other investigators involved in this research are Mathew Galsky, MD, at the Icahn School of Medicine at Mount Sinai in New York; Yohann Loriot, MD, MSc, at the Institute Gustave Roussy in Villejuif, France; Nancy Dawson, MD, at Georgetown University in Washington, DC; Andrea Necchi, MD, at the Instituto Nazionale dei Tumori in Milan, Italy; Sandy Srinivas, MB, at Stanford University in Palo Alto, Calif.; Richard Joseph, MD, at the Mayo Clinic in Jacksonville, Fla.; Ulka Vaishampayan, MD, at the Karmanos Cancer Institute in Detroit, Mich.; Srikala Sridhar, MD, MSc, at Princess Margaret Cancer Centre in Toronto, Canada; David Quinn, MBBS, MD, at the University of Southern California in Los Angeles; Alexandra Drakaki, MD, at the University of California, Los Angeles; Ignacio Duran, MD, at Hospital Universitario Virgen del Rocio in Seville, Spain; Thomas Powles, MD, at Queen Mary University in London; Jean Hoffman-Censitis, MD, at Thomas Jefferson University Hospital in Philadelphia; Na Cui, PhD; Sanjeev Mariathasan, PhD; Ann-Christine Thastrom; and Oyewale Abidoye, MD, all of Genentech in South San Francisco; and Jonathan Rosenberg, MD, and senior study investigator Dean Bajorin, MD, both at Memorial Sloan Kettering Cancer Center in New York.
Media Inquiries
David March
Phone: 212-404-3528
david.march@nyumc.org
